MedPath

Robotic-arm Assisted Ga-68 PSMA PET/CT Guided Transgluteal Prostate Biopsy

Not Applicable
Completed
Conditions
Prostate Cancer
Interventions
Diagnostic Test: Robotic arm assisted PSMA PET/CT guided prostate biopsy
Registration Number
NCT05022576
Lead Sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Brief Summary

Gallium-68 prostate-specific-membrane-antigen (Ga-68 PSMA) PET/CT is being used in Prostate cancer imaging. In the present study, we aimed to evaluate the efficacy and safety of robotic arm-assisted Ga-68 PSMA PET/CT-guided transgluteal prostatic biopsy.

Seventy-eight participants with a clinical suspicion of PCa were recruited from January 2019 to September 2020. All the patients underwent whole-body Ga-68 PSMA PET/CT. The patients with PSMA-avid lesion in the prostate underwent robotic arm-assisted PET-guided transgluteal biopsies. The degree of pain during the procedure, procedure-related complications and histopathology were evaluated.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
78
Inclusion Criteria

i. Clinically or biochemically suspected cases of Ca Prostate. ii. Patients with PSMA avid lesion in the prostate iii. Patients, who were ready to give written informed consent for biopsy iv. In good general condition (Karnofsky performance status, KPS, of more than 70).

Exclusion Criteria

i. No focal PSMA expressing lesion in the prostate ii. Patients who refused to give written informed consent iii. Abnormal coagulation profile iv. Acute prostatitis, any severe acute or chronic medical condition

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
PSMA PET/CT guided biopsy armRobotic arm assisted PSMA PET/CT guided prostate biopsyGa-68 PSMA PET/CT imaging is now routinely done in patients with prostate cancer with biochemical recurrence, response evaluation and even in patients with clinical suspicion of prostate cancer. In the present study, we aim to plan robotic arm-assisted Ga-68 PSMA guided transgluteal prostatic biopsies.
Primary Outcome Measures
NameTimeMethod
Safety of the procedureSeven days

The periprocedural and post procedural adverse effects were documented

The diagnostic yield of the procedurethree months

Obtaining a biopsy specimen from the PSMA expressing site of the prostate in patients with clinical suspicion of prostate cancer to establish a pathological diagnosis.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Department of Nuclear Medicine, PGIMER

🇮🇳

Chandigarh, Chandīgarh, India

© Copyright 2025. All Rights Reserved by MedPath